EKC Industry Forum 2025 Networking Platform

26 Aug 2025 | Vienna, Austria

HomeAgendaKeynote SpeakersParticipantsMarketplace
Register
Register
Register

Yellowstone Biosciences

Academia, R&D institution

yellowstonebio.com/Oxford, United Kingdom
1 profile visit

About

Yellowstone Biosciences is a biotechnology company advancing a novel class of cancer immunotherapies based on soluble bispecific T cell receptor (TCR) therapeutics. Our platform leverages clinically validated, non-subclonal peptide-HLA class II (pHLA-II) targets identified in patients with acute myeloid leukaemia (AML) who have been cured by allogeneic stem cell transplantation (allo-SCT). Yellowstone is pioneering the use of Class II HLA-restricted antigens to generate highly selective, off-the-shelf immune therapeutics with broad applicability in haematological malignancies and solid tumours.

LIFE SCIENCES

BiomedicalCell & Molecular BiologyTherapy and physical medicine

NETWORKING INTERESTS

Research & DevelopmentStrategic Partner

Additional questions

NETWORKING/COLLABORATION INTERESTS?

Investor looking for EntrepreneursResearch & DevelopmentStrategic PartnerFunding oportunities

Representatives

Research Scientist

Yellowstone Biosciences